Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?

Feb 28 2011

• By The Pink Sheet Daily

Related Content

Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says

Feb 08 2011

Rare Disease Improvements Planned Soon, And Up To Five Years From Now

Feb 07 2011

CSL Behring's Corifact Clears FDA On 14-Patient Trial

Feb 17 2011

Sen. Brownback Wants FDA To Aggressively Coordinate Drug Development For Neglected/Rare Diseases

Jun 24 2010

Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Feb 01 2010

FDA Approves Drug For Rare Disease Without Clinical Trial

Mar 19 2010

Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

Jul 05 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window